Summary of significant treatment × time effect. حسب Wensheng Xiao (16557866)

Study selection criteria. حسب Filip Stanicic (17808254)

الموضوعات:

PICOS criteria for the SLR. حسب Filip Stanicic (17808254)

الموضوعات:

PRISMA flow chart. حسب Filip Stanicic (17808254)

الموضوعات:

Summary of significant single-arm time effect. حسب Wensheng Xiao (16557866)

The linearly decreasing convergence factor a. حسب Junhao Wei (6816803)

Distribution of continuous variables of all 3 visits of group 1 (placebo) and group 2 (placebo) that have no significant difference among the groups. حسب Nattapon Riengvirodkij (11268720)

الموضوعات:

Supplementary file 1_Intercropping of short- and tall-stature maize decreases lodging risk without yield penalty at high planting density.docx حسب Jianhong Ren (2186293)

"…Compared with IND, IHD did not significantly improve the population yield. The upper leaf area of intercropped XY was greater than sole stand, leading to increased interception of photosynthetically active radiation (PAR). …"

Study-related adverse events. حسب Benjamin R. Lewis (22279166)

الموضوعات:

Study flow chart. حسب Benjamin R. Lewis (22279166)

الموضوعات:

Study CONSORT diagram. حسب Benjamin R. Lewis (22279166)

الموضوعات:

Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

"…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…"

Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

"…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…"

Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

"…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…"

Overview of the WeARTolerance program. حسب Ana Beato (20489933)

الموضوعات:

Bluetooth beacons with colour coded lanyards. حسب J Mark Ansermino (13958512)

الموضوعات:

Brain regions with significantly decreased activations for the Raven task are shown in blue. حسب Morteza Fattahi (15892028)

Structural equation models raw data. حسب K. Kanoho Hosoda (19929050)

الموضوعات:

Summary of sample descriptive statistics. حسب K. Kanoho Hosoda (19929050)

الموضوعات:

Characteristics of census tracts that are projected to have high (groups: 250-399 and 400+) and low (groups: 50-99 and 100-249) MHC utilization for COVID-19 vaccination before Marc... حسب Fatih Gezer (21485468)